Search results

Evidence-based recommendations on pegylated liposomal irinotecan (Onivyde) for treating pancreatic cancer in adults.

Result type

Technology appraisal guidance

Published

26 April 2017

NICE is unable to make a recommendation on pegylated liposomal irinotecan plus oxaliplatin, 5-fluorouracil and leucovorin for untreated metastatic pancreatic cancer in adults. This is because the company did not provide an evidence submission.

Result type

Technology appraisal guidance

Published

2 April 2025

This guideline covers diagnosing and managing pancreatic cancer in adults aged 18 and over. It aims to improve care by ensuring quicker and more accurate diagnosis, and by specifying the most effective treatments for people depending on how advanced their cancer is.

Result type

NICE guideline

Published

7 February 2018

Past technology appraisal appeals and decisions